Parabilis Medicines Profit Margin

Parabilis Medicines (PBLS) currently reports a profit margin of -115483.11% as of June 2026. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore Parabilis Medicines's profit margin history and peer comparisons.

Parabilis Medicines's profit margin of -115483.11% is lower than the Healthcare sector average of 9.48%. That is roughly 1218152.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Parabilis Medicines's current -115483.11% should be judged against Healthcare norms (sector average: 9.48%) and against PBLS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -115483.11%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Parabilis Medicines, and consider following PBLS for alerts when major investors trade the stock.

Parabilis Medicines is classified in the Healthcare sector. On profit margin, it currently shows -115483.11% versus a sector average near 9.48%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PBLS with unrelated industries.